{"entity":{"id":"idea-cd30-car-t-hodgkin","kind":"idea","name":"CD30 CAR-T for multiply relapsed Hodgkin lymphoma","aka":[],"tldr":"Engineer T cells against CD30 for the few patients who fail brentuximab, PD-1 blockade and transplant.","summary":"For the few patients with Hodgkin lymphoma who relapse after brentuximab vedotin, PD-1 blockade and transplant, this idea proposes CAR-T cells engineered against CD30. CD30 is expressed on nearly all Reed-Sternberg cells, shed CD30 does not block binding at therapeutic doses, and the inflamed microenvironment supports CAR-T trafficking. Phase 1/2 studies at UNC and Baylor and of the Tessa Therapeutics TT11 product produced responses and complete remissions in a substantial share of patients, although durability was modest, and the pivotal CHARIOT study was halted for business reasons in 2023 to 2024. The hypothesis is that CD30 CAR-T after PD-1 failure yields durable remissions and that PD-1 blockade prolongs persistence, tested in a randomised phase 2, at an early clinical stage.","asOf":"2026-09-07","links":[{"label":"Ramos et al., Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma (Journal of Clinical Oncology 2020)","url":"https://doi.org/10.1200/JCO.20.01342"}],"tags":[],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["car-t"],"targets":["cd30"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020","paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017","paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"CD30 CAR-T after PD-1 failure yields durable CR in ≥40% of patients with an acceptable CRS profile, and combination with PD-1 blockade prolongs persistence.","rationale":"CD30 is near-universal on Reed-Sternberg cells and shed CD30 does not block binding at therapeutic doses; the inflamed microenvironment supports CAR-T trafficking.","test":"Randomised phase 2 of CD30 CAR-T ± nivolumab vs investigator's choice in triple-refractory disease.","maturity":"early-clinical"},"route":"/ideas/idea-cd30-car-t-hodgkin/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/"}],"paper":[{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020","kind":"paper","name":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020/"},{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015","kind":"paper","name":"Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015/"},{"id":"paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017","kind":"paper","name":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","route":"/key-papers/paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}